Llusern Scientific — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Llusern Scientific is a private, commercial-stage diagnostics company tackling the global challenge of UTI diagnosis with its Lodestar DX system. This point-of-care molecular test delivers results in 35 minutes with up to 97% accuracy for key pathogens, enabling immediate, informed treatment decisions. The technology addresses critical issues of antibiotic stewardship and delayed lab results. With UK CA marking and patent filings, the company is positioned to capture market share in both human and veterinary point-of-care diagnostics.

Infectious Disease

Technology Platform

Rapid point-of-care molecular testing platform (Lodestar DX) for pathogen detection. Delivers results in 35 minutes without complex DNA/RNA extraction or lab equipment. Detects key uropathogens with up to 97% accuracy.

Opportunities

The global push for antimicrobial stewardship creates a powerful tailwind for rapid diagnostics that enable targeted antibiotic use.

The high prevalence of UTIs and the inadequacy of current standard tests (slow culture, inaccurate dipsticks) represent a large, addressable market in human and veterinary medicine.

Risk Factors

Commercialization risk includes convincing healthcare systems to adopt a new, likely higher-cost technology.

The company faces competition from larger diagnostic firms and must navigate regulatory and reimbursement hurdles in new markets beyond the UK.

Competitive Landscape

Competitors range from large diagnostic companies offering central lab molecular tests to other point-of-care molecular startups. Traditional dipsticks and lab culture remain the entrenched, low-cost incumbents. Llusern competes on speed (35 min vs. 24+ hours) and accuracy versus dipsticks.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →